Telix Pharmaceuticals Limited

ASX:TLX.AX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Australia

Market Cap

USD 5.38 B

Share Price

USD 16.06

Avg Daily Volume

1,567,502

Change (1 day)

-0.86%

Change (1 year)

33.04%

Change (YTD)

5.45%

Telix Pharmaceuticals Limited Share Price on June 20, 2025: USD 16.06

Telix Pharmaceuticals Limited Share Price is USD 16.06 on June 20, 2025, a 33.04% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Telix Pharmaceuticals Limited 52-week low Share Price is USD 19.75 on June 20, 2025, which is 22.98% above the current Share Price.
Telix Pharmaceuticals Limited 52-week low Share Price is USD 11.38 on June 20, 2025, which is -29.16% below the current Share Price.
Telix Pharmaceuticals Limited average Share Price for the last 52 weeks is USD 15.26.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

ASX: TLX.AX

Telix Pharmaceuticals Limited

CEO	Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA
IPO Date	Nov. 14, 2017
Location	Australia
Headquarters	55 Flemington Road
Employees	415
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.